KOL Pulse Insights Blog

RASONQUE FAERS Report Has the Revolution Medicines CEO Spooked

Written by Brian Shields | Nov 19, 2026, 8:15:50 PM

Key takeaways

  • FDA approved Rasonque (daraxonrasib) on August 26, 2026. More than 5,000 US patients got it in five weeks, at a list price of about $39,800 a month.
  • In the first 11 weeks, FAERS (FDA Adverse Event Reporting System) received 354 Rasonque reports; 224 list death. Revolution Medicines submitted 351 of the 354, including 222 of the death reports.
  • November 16: asked about tolerability and a "prominent media report" (the analyst meant Ben Sasse's rash), CEO Mark Goldsmith assumed it was FAERS and called the short analysis "total nonsense."
  • RASolute 302 enrolled ECOG 0–1 patients with a median age of 66. The FDA label also covers patients who are "not candidates for multiagent systemic therapy," a group RASolute 302 did not test.
  • On the Q3 earnings call, Revolution Medicines said "a meaningful portion" of its first patients were "lower performance status," sicker than the trial population. Asked about real-world tolerability, it said "so far, so good" and gave no data.
  • In FAERS, 114 consumer reports describe hospitalization.
  • The KOL community discussed the potential risks of treating frail pancreatic cancer patients with RASONQUE upon the drug's media hype

The numbers

FDA approved Rasonque (daraxonrasib), Revolution Medicines' oral RAS(ON) inhibitor, on August 26, 2026, for previously treated metastatic pancreatic cancer. In RASolute 302, median overall survival was 13.2 months vs 6.7 months with chemotherapy (FDA). More than 5,000 US patients were on commercial drug by September 30, about five weeks after approval (Revolution Medicines).

The list price is about $39,800 for a 30-day supply, roughly $477,000 a year (AP; SEC filing via Yahoo Finance). Third-quarter net revenue was $197.6M. On the earnings call, the company said about 2,700 providers prescribed Rasonque in the quarter, 60% of use in community practices and 40% in academic centers (Q3 call, via Yahoo Finance). The 10-Q says Q3 revenue reflects patient demand and initial stocking of the distribution channel (10-Q). In the Q3 Conference all, Anthony Mancini, Chief Global Commercialization Officer, said early demand comprised three cohorts:

👉EAP (Early Access Program) patients transitioning to commercial supply (many already on therapy for several months),

👉a sizable finite cohort of patients who had exhausted available options and were awaiting an approved treatment (a meaningful portion of whom are later-stage, lower performance status patients who may have shorter treatment durations),

👉and newly eligible patients initiating RASONQUE post-approval

Lower Perfomance status patients, ECOG PS > 2, were not included in the RASolute302 clinical trial

I pulled the public FAERS data. FDA received 354 Rasonque reports in the first 11 weeks after approval. 224 list death as an outcome.

November 11: the short report

RVMD fell 6.4% on November 11 while the XBI rose 0.8% (Trefis). STAT's Adam Feuerstein attributed the drop to a short report from Favus Institutional Research ("It was Favus," X) and summarized its thesis:

We have not seen the Favus report, its methods or any short-position disclosure. Its thesis is described here only as Feuerstein and Leerink characterized it.

Leerink Partners called the interpretations fundamentally flawed and recommended buying the dip (Leerink note shared on X). Leerink quotes the short analysis as assuming "2-3 patient deaths/day not reported to FDA for every death on Rasonque that is reported to FDA." Leerink called that assumption arbitrary. FAERS cannot confirm or refute it.

Leerink also said the analysis counted deaths by the date FDA received each report, not the date the company received it, which bunches deaths into recent weeks. We checked our export. Of the 167 death reports FDA logged in November, 107 had reached the company in September or October. Median lag: 8 days.

By the date the company received them, death reports still rose with uptake: 12 in September, 151 in October and 59 in the first 12 days of November.

Leerink estimates Rasonque sales of more than $440M in Q4 2026 and more than $2B in 2027. Those are Leerink's figures. This is not an investment note.

November 16: the CEO answers a question nobody asked

 

Revolution Medicines CEO, president and board chair Mark Goldsmith spoke at the Jefferies Global Healthcare Conference in London. Jefferies senior biotech analyst Faisal Khurshid asked about tolerability (transcript):

Faisal Khurshid (Jefferies): Got it. Mark, can I just ask you to sort of double-click on the point around tolerability? You spoke to the exceptional efficacy and quality of life outcomes that you saw in the study. For a couple of reasons, there was a prominent media report, and also, I think part of it is that there is not much else to pick at. Investors have kind of really concerned themselves to some extent with the tolerability profile of RASONQUE. Can you speak about what exactly you are doing to kind of ease any friction in the real world and what kind of results and feedback you are getting from the treating physicians?

After a general discussion of RASH management on RASONQUE, Goldsmith assumed the "prominent media report" was the FAVUS Short report on the FAERS:

Mark Goldsmith (Revolution Medicines): May I just say, though, you said there were some reports about it, and I don't know, you said public reports. Were you alluding to the FAVUS report or something like that?

Faisal Khurshid (Jefferies): No, we can talk about that if you want.

Mark Goldsmith (Revolution Medicines): I'm not talking about it.

Faisal Khurshid (Jefferies): No, I was talking about the—

Mark Goldsmith (Revolution Medicines): It can be very short. It's total nonsense. They took a database that they didn't understand, and they came to conclusions that didn't mean anything.

He continued: "We're not aware of any public reports of any substance that would affect how people perceive it." Then Khurshid clarified:

Faisal Khurshid (Jefferies): Got it. Okay. Yeah, no, I was referring to the Ben Sasse interview where I think people saw that, and I think from the investment community, we're used to looking at things on paper and spreadsheets. I don't think people appreciated what a grade three rash actually looks like, so that's what I was referring to.
Mark Goldsmith (Revolution Medicines): Yeah, I can't, of course, speak specifically to any patient's individual case. There are rare cases of individuals who will have a severe skin side effect like that. I can't really even comment on whether that senator was even taking RASONQUE. But, we have seen some cases of that. They're uncommon. Typically, that means that somebody didn't deal with it early on when the rash started to occur and continued to treat at the same dose and without any break. Sun exposure also substantially contributes to it. Again, we found, based on the objective data from the 302 study and everything we've heard from physicians, so far today, that it's very uncommon for somebody to desire to discontinue RASONQUE.

 

What's wrong with the CEO's message:

Sen Ben Sasse has been treated at MD Anderson Cancer Center under clinical trial protocol with specialized support from a Dermatological Oncology Team for his rash. He has experienced a "nuclear" full body rash, despite this top tier medical care and support. The fine RevMED CEO shouldn't blame the rash on "Somebody".

The analyst asked about a rash. The CEO brought up FAERS and the short report himself. STAT's Adam Feuerstein posted the FAERS portion that morning, introducing it as Goldsmith addressing the Favus report:

Feuerstein's post names the analyst Faisal Rashid; the transcript says Faisal Khurshid.

What the CEO did not say

Goldsmith raised the FAVUS report on FAERS on his own and dismissed the short seller's reading of the database. He did not address the reports themselves: how many came through the company, what the patients died of, what follow-up found, the performance status of the patients that died, or if the deaths were preceded by hospitalization due to adverse events. He just dismissed the analysis of the FDA database as "nonsense."

Revolution Medicines submitted 351 of the 354 reports (99%), including 222 of the 224 death reports. Three reports went directly to FDA. Of the 351 company-submitted reports, 277 came from consumers and 74 from healthcare professionals. Sponsors must forward serious, unexpected reports to FDA within 15 days and follow up for more detail (21 CFR 314.80). The public sees the coded fields provided to the FDA through these reports. 

How to read FAERS

FAERS collects reports from patients, caregivers, physicians and companies (FDA). FDA states that a report "does not establish causation," that "information in reports has not been verified," and that the data "cannot be used to calculate the incidence" of an event (FDA). Most of the reports are captured by the manufacturer's team and submitted by this team to the FDA's FAERS.

What the reports describe

Consumers (patients and families) describe diarrhea, dehydration, vomiting, rash, nausea and mouth sores. 114 consumer reports describe hospitalization, vs 4 from HCPs.

Source: FDA FAERS public export, KOL Pulse analysis. Shares of reports, not incidence.

Rash, diarrhea and stomatitis are on the label and were common in the trial (label). 

One HCP report in this export describes Stevens-Johnson syndrome/toxic epidermal necrolysis but is coded "Non-Serious."

Real-world patients vs RASolute 302

RASolute 302 enrolled patients with ECOG 0–1 who had one prior regimen in the metastatic setting (OncLive). Median age was 66; about half were 65 or older and about 1 in 6 were 75 or older. FDA noted the typical US age at diagnosis is about 71 (FDA review). Fatal adverse events: 2.1% on daraxonrasib vs 1.9% on chemotherapy. FDA reviewers called the fatal events on drug "representative of known complications" of advanced cancer (same review).

A physician's read of the trial

Vinay Prasad, MD, MPH, posted this review of RASolute 302 after ASCO 2026 (Substack, May 31, 2026):

RASolute 302 trial has rightly generated significant excitement at ASCO2026 and I share this excitement. Pancreatic cancer has for long been a challenge for oncologists and KRAS is the classic ‘undruggable’ target. Any advance here is notable and must be celebrated. However no trial is perfect and an honest appraisal will help design better studies and develop safer and more effective therapies. It is in this spirit that I delve into the details of trial.

I have just four points

1. 100% of people on the experimental drug eventually progress. There is no curative subset. This is disappointing and different than other agents such as immunotherapy, where there can be cures.

2. 15% of the control arm declines treatment but only 3% of the intervention arm does not recieve therapy. A difference of 12%. These people are likely not random dropouts but the highest socioeconomic status participants with best alternatives. The drop out is patient disappointment. Thus randomization is violated. We potentially have the bottom 9/10 participants (in terms of OS) compared against 10/10. (not all of these persons appear to be censored, which is good, but many are).

3. Gains in OS exceed PFS gains. This raises the question of whether experimental drug is followed by chemo while chemo is followed by hospice or some other palliative option. Thus some of the gains of the experimental drug may be due to this additional care. Yet post protocol treatments not reported to explore this further. Neither in the paper nor the supplemental appendix. This is unfortunate.

4. Daraxonrasib will be harder to give older frailer people due to side effects.

Overall: A significant step forward for patients with metastatic pancreatic cancer but much more needs to be accomplished for this disease. I hope this is only the first of other advances to come in the future.

Also continued best wishes to Ben Sasse whom I have long admired.

— Vinay Prasad, MD, MPH
Interestingly, the Wall Street Crowd were critical of Dr. Prasad's viewpoints on this stock catalyst:

 

However, the Oncology KOL Community were quick to defend Dr. Prasad's perspectives on RASONQUE and the challenges of treating patients with pancreatic cancer

 

 

Are patients too sick for Rasonque getting it?

The label is broader than the trial. It covers patients who received at least one prior therapy, or who "are not candidates for multiagent systemic therapy" (FDA). RASolute 302 did not enroll that second group. Median age in the FAERS reports is about 70.

Are you comfortable with the fact the FDA label includes patients "not candidate for multiagent chemotherapy" when we have no clue if this population would benefit?

— Timothée Olivier, MD, oncologist, Geneva, August 28, 2026 (X)
Can't wait for real world data to show that dose adjusted daraxonrasib works just as well. I'm sure a good number of our patients will need dose adjustments.

— Udhayvir Grewal, MD, GI oncologist, Winship Cancer Institute at Emory, August 26, 2026 (X)

On the Q3 earnings call on November 4, 2026, Anthony Mancini, chief global commercialization officer, described the patients who started Rasonque right after approval (transcript):

We're not providing a detailed breakdown of those, but what we can say is that a meaningful portion of those initial patients are later-stage patients that are lower performance status, and as a result, may have shorter treatment durations.

— Anthony Mancini, Chief Global Commercialization Officer, Revolution Medicines

Are patients suffering in their final days of care on RASONQUE?

Consumers (patients and families) originated nearly four in five reports. 114 consumer reports describe hospitalization, vs 4 from healthcare professionals. They describe diarrhea, dehydration, vomiting, rash, nausea and mouth sores. 224 reports list death; in about three of every four HCP reports, "Death" is the only coded term.

The best-known patient on the drug is former Sen. Ben Sasse, who took daraxonrasib in a clinical trial. He described the rash as "nuclear" on a New York Times podcast (NBC News). In September his cancer developed resistance to the drug (New York Times).

FAERS does not say how long patients were on drug before they died, or whether they were in hospice.

Are doctors throwing Hail Mary passes?

Late-line treatment in pancreatic cancer predates Rasonque. In a SEER-Medicare cohort of 3,825 patients 66 or older with stage IV pancreatic cancer who died within 12 months of diagnosis, 749 received chemotherapy in their last 30 days of life (review of Bao et al). Chemotherapy in the last 14 to 30 days of life is a standard quality measure for aggressive end-of-life care (BMC Palliative Care).

Rasonque is a daily pill with no infusion chair. That can lower the barrier to starting it in a sicker patient. Whether that is happening cannot be read from FAERS. It needs claims or EHR data showing when patients started the drug relative to death.

Are Revolution Medicines sales reps pushing the drug too hard?

There is no public evidence of improper promotion. What is public: 5,000+ patients and about 2,700 prescribers in five weeks, 60% of use in community practices, and a company that told investors it is focused on educating providers, particularly in community practice, on the label, safety profile and patient support (Q3 call, as summarized by Yahoo Finance). The 10-Q says the company expects to keep expanding its sales organization (10-Q).

The company's Q3 investor slides (Q3 call, November 4, 2026):

Q3 launch: $198M, more than 5,000 patients in about five weeks. Revenue includes EAP transitions, a backlog of waiting patients and initial distribution stocking. Field organization: 60% of patients are treated in community oncology, "focus on broad education & account reach." Strategy: "Establish RASONQUE as the new standard of care" and a franchise "spanning every major stage of disease."

No slide mentions adverse events, frail patients or performance status. One analyst asked about tolerability:

Analyst (Raymond James, on for Sean McCutcheon): Given that it is early, but could you please share some feedback you have been hearing about RASONQUE's tolerability in the real world now that use is moving more into the community? Do you have any feedback on how physicians are managing the toxicities with either the prophylaxis or the education materials you mentioned?

Mark Goldsmith: Is there anything that you want to comment on there?

Anthony Mancini: Maybe I will comment in general that our experience thus far has been very positive. We have spent a considerable focus and attention on ensuring the education around our adverse event profile. So far, so good is what I would say. I think our plans are coming to fruition. The reactions have been positive to date, but again, it is very early, so we are really focused on ensuring a positive customer experience, and so far, so good is what I would say. There is really not a lot to add at this point, but I will have a lot more to report with a full quarter under our belt.

The company gave no rates, no hospitalization data and no safety data from the community practices that account for 60% of use.

At close to $40K for a month's supply, $480K a year, I wonder if it's been priced for a pharma company looking to buy the company.

— John Carroll, founder, Endpoints News, August 26, 2026 (X)

The patient homepage

Patients searching Google for the drug see a sponsored ad: "RASONQUE Now Approved … A new treatment option has been approved." It lists patient resources and support. It names no indication and no risks.

Google sponsored result for rasonque.com, November 18, 2026.

These are screenshots of the RASONQUE patient homepage (rasonque.com/about, November 18, 2026; reached through that ad). The benefits get large numbers and bold graphics:

Overall survival: "Nearly 2X longer." Progression-free survival: "Doubled the time." Tumor response. Quality of life.

The side effects get icons:

"Serious common side effects were:" three icons, no rates, no severity. "Everyone on your care team has the same goal: to help you manage side effects and continue treatment."

What the homepage does not say, from the prescribing information (label, RASolute 302): serious adverse reactions occurred in 30% of patients. The most frequent were diarrhea (3.7%), fever (3.3%), sepsis (2.9%), fatigue (2.1%) and bleeding (2.1%). Grade 3–4 rash occurred in 13%, mouth sores in 12% and diarrhea in 7%. 69% of patients had a dose interruption and 37% a dose reduction. These were fit, ECOG 0–1 trial patients.

In FAERS, 114 consumer reports describe hospitalization. Consumers originated nearly four in five Rasonque reports.

The homepage describes the trial as adults "whose cancer progressed after prior chemotherapy." Its indication also covers people "who cannot receive a combination of cancer treatments." It does not say the trial did not test that group.

What sponsors and clinicians can do

  • Sponsors: publish the context. Exposure counts, follow-up findings and cause-of-death breakdowns. 
  • Clinicians: address the GI and skin burden early. Start rash prophylaxis before the first dose, as the label recommends, and plan for diarrhea and hydration from day one. ESMO 2026 featured a toxicity algorithm from @GIcancerDoc and @DrShubhamPant (X).
  • HCPs: submit complete reports. Cause, timing and disease status. One detailed narrative is worth more than several bare death notices.
  • Use the right data for the real-world question. Registries, RWE and Sentinel. Not FAERS.
See what oncologists are saying about RASolute 302 on KOL Pulse →

Related on KOL Pulse

Frequently asked questions

How many FAERS reports has Rasonque received?

FDA received 354 Rasonque (daraxonrasib) reports from September 12 to November 12, 2026, the first 11 weeks after approval, in KOL Pulse's pull of the public FAERS export. 224 list death as an outcome. These are report counts, not incidence.

Do Rasonque FAERS death reports mean the drug caused those deaths?

No. FDA states that a FAERS report "does not establish causation" and that "information in reports has not been verified." In about three of every four HCP reports, the only coded term is "Death."

What adverse events do patients and families report most often?

Diarrhoea, dehydration, vomiting, rash, nausea and mouth sores. Rash, diarrhea and stomatitis are on the label and were common in RASolute 302.

How did fatal adverse events compare in RASolute 302?

2.1% on daraxonrasib vs 1.9% on chemotherapy. FDA reviewers called the fatal events on drug "representative of known complications" of advanced cancer.

Can FAERS show whether Rasonque is riskier in real-world patients than in the trial?

No. That requires data with denominators: tumor registries, claims and EHR-based oncology datasets, the sponsor's postmarketing studies and FDA's Sentinel system.

Why did Revolution Medicines stock fall over Rasonque FAERS reports?

On November 11, RVMD fell 6.4% while the XBI rose 0.8%. STAT's Adam Feuerstein attributed the drop to a short report from Favus Institutional Research. We have not seen that report. Leerink called its interpretations fundamentally flawed and said it used FDA-received dates rather than company-received dates. Our check: 107 of the 167 November death reports reached the company in September or October.

What did Revolution Medicines' CEO say about the FAERS reports?

On November 16, at the Jefferies Global Healthcare Conference, a Jefferies analyst asked about tolerability and a "prominent media report." CEO Mark Goldsmith assumed he meant FAERS and called the short analysis "total nonsense" and said its authors "took a database that they didn't understand and they came to conclusions that didn't mean anything." The analyst later said he had meant the Ben Sasse interview about a grade 3 rash. Goldsmith did not describe the reports' content, causes of death, follow-up or exposure. Revolution Medicines submitted 351 of the 354 reports, including 222 of the 224 death reports.

Methods: Public FAERS export for Rasonque (daraxonrasib), 354 cases FDA received from September 12 to November 12, 2026. Analysis by KOL Pulse. Company-submitted vs direct counts use the export's Sender and Report Type fields (Expedited or Non-Expedited from Revolution Medicines vs Direct). Percentages and counts are shares of reports, not incidence.

Disclaimer: This post is for information only and is not investment, medical or regulatory advice. KOL Pulse makes no claims about the efficacy or safety of any product. FAERS reports are unverified and do not establish causation. Quotes are reproduced verbatim from public sources. Leerink's figures are as stated in its note shared on X. We did not have access to the Favus Institutional Research report, so its thesis is described only as characterized by STAT's Adam Feuerstein and by Leerink. Short sellers and sell-side firms may have financial interests in the stocks they cover.